DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025.

DexCom, Inc., a global leader in real-time continuous glucose monitoring for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM device that easily tracks real-time glucose ...

DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.

DexCom's Q3 results showed disappointing 2% revenue growth and a 26% decline in operating income. Click here to read my DXCM stock's earnings review.

Suffice it to say, though, that assuming you have a Dexcom sensor for glucose monitoring, the Oura app will now be able to ingest that data for easy viewing and also show it in line with other ...

Dexcom receives FDA clearance for first OTC glucose sensor The diabetes tech firm tailored its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin.

DexCom, Inc., v. Abbott Diabetes Care, Inc.: Federal Circuit Finds Forum Selection Clause Does Not Bar IPR Proceedings Based on Contract Interpretation ...

Dexcom announced that its G7 diabetes sensor can now link directly to a user’s Apple Watch, allowing them to track their glucose readings in real-time even if their iPhone isn’t nearby.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years.

Dexcom’s first-ever State of Type 2 Report features survey findings from people with Type 2 diabetes and reveals majority of respondents struggle with anxiety and depression1.

DexCom, Inc., the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. She currently serves as President and ...

SAN DIEGO, March 10, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective ...